Moderna : Postpandemic transition makes itself felt
>Resizing measures weigh on P&L - Moderna reported its Q3 2023 results yesterday evening. Sales came in at $ 1.8bn (vs $ 1.3bn forecast). As expected, Spikevax sales fell sharply (-44%) despite market share gains in the US since the start of the year (45% ytd vs 36% in 2022). On the operating front, COGS doubled to $ 2.2bn due to the booking of resizing costs ($1.4bn) to adapt the group's industrial base to the transition to a post-pandemic situation. EBIT totalled -...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.